ArticleGeriatrics (Basel, Switzerland)2024
Cost-Effectiveness of GaitSmart and an Artificial Intelligence Solution for Rehabilitation of Patients Undergoing Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) in Older Population in the United Kingdom.
Article in Geriatrics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Economic evaluation of AI-assisted technologies in healthcare: A systematic review.Journal of food and drug analysis · 2025Pooled it
- Assessing the Value for Money of AI-Assisted Technologies for Older Adults: Scoping Review of Economic Evaluations.Journal of medical Internet research · 2026Article
- Artificial Intelligence in Arthroplasty: A Comprehensive Structured Critical Review and Descriptive Evidence Map of Validation, Uncertainty, and Workflow Integration.Bioengineering (Basel, Switzerland) · 2026Review
- The Digital Transformation of Rehabilitation Medicine: A Narrative Review of Artificial Intelligence Innovations, Clinical Integration, and Future Paradigms.Journal of evaluation in clinical practice · 2026Review
- From One-Size-Fits-All to Data-Driven Recovery: A Narrative Review of Wearable Technologies Toward Personalized Rehabilitation After Total Hip and Knee Arthroplasty.Journal of personalized medicine · 2026Review
- Optimizing arthroplasty outcomes: the impact of artificial intelligence and robotic assistance.Annals of medicine and surgery (2012) · 2026Review
- Telerehabilitation in Hip and Knee Arthroplasty: A Narrative Review of Clinical Outcomes, Patient-Reported Measures, and Implementation Challenges.Journal of functional morphology and kinesiology · 2025Review
- Anxiety and depression status in geriatric patients undergoing total hip arthroplasty: Correlation with postoperative pain and risk factors.World journal of psychiatry · 2025Article
- GaitSmart Rehabilitation Exercise Programme for Gait and Mobility Issues: A NICE Medical Technologies Guidance.Applied health economics and health policy · 2025Review
- The Role of Artificial Intelligence and Emerging Technologies in Advancing Total Hip Arthroplasty.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGaitSmart (GS) is a sensor-based digital medical device that can be used with the integrated app vGym to provide a personalised rehabilitation programme for older people undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA). This study aimed to determine whether the GS intervention used in the rehabilitation of older people undergoing THA or TKA is potentially cost-effective compared to the current standard of care (SoC).
methodsDecision-analytic modelling was conducted to estimate the cost-effectiveness over a seventeen-week time horizon from an NHS perspective. UK clinical and cost data from the GaitSmart randomised clinical trial was used to obtain the input parameters, and a sensitivity analysis was performed to address uncertainties.
resultsOver a seventeen-week time horizon, GS incurred cost savings of GBP 450.56 and a 0.02 gain in quality-adjusted life years (QALYs) compared to the SoC. These results indicate that GS is the dominant intervention because the device demonstrated greater effectiveness and lower costs. Probabilistic sensitivity analyses confirm the robustness of our results.
conclusionsGS appears to offer short-term efficiency benefits and demonstrates cost-effectiveness for the improvement in gait in people undergoing THA or TKA, compared to the SoC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.